From Basic Research to Pharmaceutical Drug Discovery - a (Validated) Model for Bridging Academia to Pharmaceutical Industry
Munich Psychiatry Lecture Series | MPLS
- Cancelled!
- Date: Mar 21, 2017
- Time: 03:00 PM - 04:00 PM (Local Time Germany)
- Speaker: Bert Klebl
- Lead Discovery Center GmbH
- Location: Department of Psychiatry and Psychotherapy, Nußbaumstraße 7, Munich
- Room: Lecture Hall
- Host: Moritz Rossner
The Lead Discovery Center GmbH (LDC) transforms results from basic research into novel drug candidates. LDC collaborates with basic researchers to leverage excellent biomedical basic research. LDC's academic network represents thousands of scientists and a large pipeline of novel ideas for treating diseases with unmet medical need. LDC has established a flexible, but industry-type drug discovery infrastructure. LDC's current portfolio contains ~20 highly innovative and collaborative drug discovery projects. LDC tries to transform these innovative early-stage projects into attractive licensing opportunities. It has built up an excellent track record in partnering projects to industrial partners, like Bayer AG, Boehringer Ingelheim, Merck KGaA, Qurient etc.
LDC collaborates with various Max-Planck institutes and other academic partners on early-stage drug discovery projects across all therapeutic indications. Currently, these include 6 active neuroscience projects, covering the identification of SLC6A15 inhibitors for stress-induced mood disorders and ErbB4 modulators for schizophrenia as well as approaches for neurodegenerative disorders. Some novel and experimental findings will be presented.
Further Information on Location:
Department of Psychiatry of the Ludwig-Maximilians-University
Nußbaumstr. 7
80336 Munich
Germany